Skip to content

    Lineage Cell Therapeutics (LCTX) stock price & financials

    View LCTX earnings calls

    Overview

    Price

    Market Cap

    Sector

    Rank

    Performance9.0% 1Y

    Financials

    Income Statement

    Financial Trajectories

    11
    Quarterly
    MetricQ3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Trend
    EarningsRevenue
    $3.78M
    $2.87M
    $1.50M
    $2.77M
    $3.68M
    -2.6%
    $6.61M
    +130.4%
    $1.73M
    +14.8%
    $1.07M
    -61.3%
    Strengthening
    Operating Profit
    -$3.84M
    -$5.11M
    -$6.50M
    -$19.78M
    -$3.79M
    +1.4%
    -$6.55M
    -28.1%
    -$7.59M
    -16.7%
    -$8.92M
    +54.9%
    Strengthening
    Net Profit
    -$3.03M
    -$3.27M
    -$4.14M
    -$30.46M
    -$29.78M
    -881.6%
    $851.0K
    -$4.81M
    -16.3%
    $1.48M
    Weakening
    EPS
    $-0.02
    $-0.02
    $-0.13
    $-0.13
    -550.0%
    $-0.02
    +0.0%
    $0.01
    Stable
    Other Income
    $839.0K
    $1.86M
    $2.36M
    -$10.58M
    -$25.97M
    -3194.9%
    $2.16M
    +16.1%
    $2.80M
    +18.7%
    $10.47M
    Strengthening
    Interest
    Depreciation
    Profit before Tax
    -$3.00M
    -$3.25M
    MarginsOPM
    -101.6%
    -178.2%
    -433.1%
    -715.4%
    -102.8%
    -1.2%
    -99.1%
    +44.4%
    -440.2%
    -1.6%
    -834.7%
    -16.7%
    Strengthening
    Tax
    0.0%
    0.0%
    ReturnsROIC
    -5.8%
    -6.3%
    -8.0%
    -58.7%
    -57.4%
    -881.6%
    1.6%
    -9.3%
    -16.3%
    2.9%
    Weakening

    Balance Sheet

    Balance Sheet

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    AssetsCash & Equivalents$23.59M$9.50M$32.59M$55.74M$11.36M$35.44M$45.79M$40.79M$37.35M
    Short-Term Investments$7.15M$21.22M$8.98M$2.62M$46.52M$50.0K$2.02M$14.99M$13.47M
    Total Current Assets$36.36M$57.52M$44.00M$111.55M$60.00M$38.44M$51.00M$59.16M$52.97M
    Net PP&E$5.83M$8.95M$5.84M$4.87M$5.67M$4.77M$4.39M$4.70M$4.48M
    Goodwill$10.67M$10.67M$10.67M$10.67M$10.67M$10.67M$10.67M$10.67M
    Intangibles$3.13M$48.25M$47.03M$46.82M$46.69M$46.56M$46.54M$31.70M$31.70M
    Total Assets$101.66M$125.48M$107.95M$174.54M$123.66M$101.02M$113.22M$112.58M$106.22M
    LiabilitiesTotal Current Liabilities$6.81M$6.49M$7.77M$47.12M$18.98M$17.96M$13.98M$11.37M$8.02M
    Short-Term Debt
    Long-Term Debt
    Long-Term Leases$1.85M$3.87M$2.51M$1.94M$2.86M$1.98M$1.29M$1.53M$1.33M
    Total Liabilities$9.41M$14.23M$12.82M$83.65M$51.73M$39.00M$36.21M$69.24M$46.42M
    EquityCommon Stock & APIC$354.27M$387.06M$393.94M$434.53M$440.28M$451.34M$484.72M$515.47M$535.72M
    Retained Earnings-$261.86M-$273.42M-$294.08M-$337.10M-$363.37M-$384.86M-$403.46M-$467.00M-$470.33M
    Total Equity$92.25M$112.96M$96.20M$92.22M$73.34M$63.42M$78.38M$44.55M$60.92M
    HighlightsNet Cash / (Debt)

    Cash Flow

    Cash Flow

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    ActivitiesCash from Operating-$30.88M-$31.95M-$19.75M-$23.56M$1.06M-$28.57M-$23.09M-$18.92M-$23.82M
    Cash from Investing$11.82M$16.96M$13.04M$9.74M-$46.16M$46.45M-$2.31M-$13.46M-$13.71M
    Cash from Financing$5.77M$617.0K$29.86M$36.93M$1.63M$6.42M$35.86M$26.95M$32.24M
    SummaryCapital Expenditure-$556.0K-$440.0K-$64.0K-$340.0K-$413.0K-$674.0K-$565.0K-$522.0K-$574.0K
    Free Cash Flow-$31.44M-$32.39M-$19.82M-$23.90M$646.0K-$29.24M-$23.66M-$19.44M-$24.39M
    FCF Margin-630.3%-921.4%-1085.3%-550.6%4.4%-326.9%-249.0%-133.6%-186.4%

    Ratios